Delia D, Bonati A, Giardini R, Villa S, De Braud F, Cattoretti G, Rilke F
Hematol Oncol. 1986 Jul-Sep;4(3):237-48. doi: 10.1002/hon.2900040308.
The T1 surface antigen (CD5,p67) expression on blood lymphocytes (PBL) and lymphoid cells from lymph node biopsies (LN) from 31 patients with B-cell chronic lymphocytic leukemia (B-CLL) and 79 with B non-Hodgkin lymphoma (B-NHL), was detected in 25 B-CLL (80 per cent) and in 11 B-NHL (13 per cent) belonging to the following histologic subtypes: lymphocytic of CLL type (DLWD) one case, lymphoplasmacytoid (DLWD) four cases, centrocytic (DLPD) five cases, immunoblastic (DH) one case. All B-CLL and the T1 + B-NHL were also tested with monoclonal antibodies against the Common Acute Lymphoblastic Leukemia Antigen, B cells (FMC7, FMC8, BA1, Y29-55), T cells (OKT11a), HLA-DR and HLA-DQ monomorphic determinants. All the B-CLL and the T1+ B-NHL were CALLA-, BA1+, Y29.55+. FMC7+ cells were detected in large numbers six B-CLL (three T1+ and three T1-) and in four centrocytic lymphomas. FMC8 reacted with 70 per cent of leukemias (where it stained 30 per cent of neoplastic cells) and with 8/9 T+ B-NHL. HLA-DR and HLA-DQ molecules were detected in 100 per cent and 90 per cent of cases respectively. In vitro treatment of HLA-DQ- or T1- B-CLL with phorbol ester TPA led to the expression of these antigens as well as of the receptors for Interleukin 2 and MLR3 activation antigen. Surface membrane Ig (SIg) was detected in 79 per cent of cases, its density measured by FACS analysis varied, even markedly, from case to case. Among the B-CLL, cells with high SIg content were either T1+ or T1- and more likely FMC7+. The SIg- cases were seven B-CLL (five T1+ and two T1-) and two B-NHL, in which, however, cytoplasmic IgM was detected. This study reveals the existence of four major B-CLL subgroups: T1- SIg-, T1+ SIg+, T1+ SIg+, T1- SIg+. It also indicates that the T1 antigen may be transitionally present during B-cell differentiation and that its expression may precede that of SIg as supported by the in vitro studies. In addition, the finding that some B-NHL are T1+ suggests that they derive similarly to the B-CLL from a common progenitor.
检测了31例B细胞慢性淋巴细胞白血病(B - CLL)患者的外周血淋巴细胞(PBL)和淋巴结活检(LN)的淋巴样细胞以及79例B非霍奇金淋巴瘤(B - NHL)患者的T1表面抗原(CD5,p67)表达情况。在25例B - CLL(80%)和11例B - NHL(13%)中检测到该抗原表达,这些B - NHL属于以下组织学亚型:CLL型淋巴细胞样(DLWD)1例、淋巴浆细胞样(DLWD)4例、中心细胞样(DLPD)5例、免疫母细胞样(DH)1例。所有B - CLL和T1 + B - NHL还用抗常见急性淋巴细胞白血病抗原、B细胞(FMC7、FMC8、BA1、Y29 - 55)、T细胞(OKT11a)、HLA - DR和HLA - DQ单态决定簇的单克隆抗体进行了检测。所有B - CLL和T1 + B - NHL均为CALLA -、BA1 +、Y29.55 +。在6例B - CLL(3例T1 +和3例T1 -)和4例中心细胞淋巴瘤中大量检测到FMC7 +细胞。FMC8与70%的白血病反应(其中它对30%的肿瘤细胞染色)以及与8/9 T + B - NHL反应。分别在100%和90%的病例中检测到HLA - DR和HLA - DQ分子。用佛波酯TPA对HLA - DQ -或T1 - B - CLL进行体外处理导致这些抗原以及白细胞介素2和MLR3激活抗原的受体表达。在79%的病例中检测到表面膜Ig(SIg),通过FACS分析测量其密度在不同病例中有所不同,甚至差异明显。在B - CLL中,具有高SIg含量的细胞要么是T1 +要么是T1 -,且更可能是FMC7 +。SIg -的病例有7例B - CLL(5例T1 +和2例T1 -)和2例B - NHL,然而在其中检测到了细胞质IgM。本研究揭示了存在四个主要的B - CLL亚组:T1 - SIg -、T1 + SIg +、T1 + SIg +、T1 - SIg +。这也表明T1抗原可能在B细胞分化过程中短暂存在,并且如体外研究所支持的,其表达可能先于SIg。此外,一些B - NHL是T1 +这一发现表明它们与B - CLL一样源自共同的祖细胞。